Insilico expands Tenacia CNS pact in deal worth up to $94.75M
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology have expanded their central nervous system drug discovery partnership, adding a second AI-designed program and bringing the new deal’s potential value to as much as $94.75 million. The companies said on March 26, 2026 that the broadened agreement builds on a March 2025 collaboration focused on small-molecule inhibitors with blood-brain barrier permeability for CNS use. Under the expanded pact, Insilico will use its Pharma.AI platform with Tenacia’s CNS expertise and proprietary data to advance an additional candidate to the preclinical candidate stage, with Insilico eligible for near-term and milestone payments. Tenacia is a Bain Capital-backed neuroscience company founded in 2022, while Insilico has been widening its AI-partnering activity following its December 30, 2025 Hong Kong listing, including a separate multiyear Eli Lilly collaboration that could be worth up to about $2.75 billion plus tiered royalties and includes $115 million upfront for multiple programs across therapeutic areas. In that Lilly deal, Lilly received exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for selected indications, while the companies also agreed to work on Lilly-selected targets using Pharma.AI. (prnewswire.com; pharmashots.com)
Why it matters: For veterinary professionals, this isn’t a companion animal product story, but it is another signal that AI-enabled CNS discovery is moving from platform promise into repeat business and milestone-based partnerships. Neurology remains one of the harder areas in drug development because brain exposure, target selection, and translational risk are all major hurdles, so a collaboration explicitly centered on blood-brain barrier-penetrant molecules is worth watching as a marker of where computational discovery is being applied most aggressively. The parallel Lilly deal also reinforces that larger drugmakers are still willing to pay substantial upfronts for AI-enabled access to preclinical assets and target-focused discovery programs. Insilico also says its platform work extends into veterinary medicine, which means advances in CNS design tools developed for human health could eventually influence animal health R&D workflows, licensing models, or partner expectations. (prnewswire.com; pharmashots.com)
What to watch: Watch for disclosure of the target, preclinical candidate timing, and whether either company signals crossover plans for broader neuroscience or animal health applications. It will also be worth watching whether Insilico continues to pair disease-specific collaborations like Tenacia with larger platform-and-asset deals like the Lilly agreement. (prnewswire.com; pharmashots.com)